Companies sponsors |
Eli Lilly (selpercatinib) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
Asthma + Lung UK |
|
Black Health Agency for Equality |
|
Cancer Black Care |
|
Cancer Equality |
|
Helen Rollason Cancer Charity |
|
Independent Cancer Patients Voice |
|
Macmillan Cancer Support |
|
Maggie’s Centres |
|
Marie Curie |
|
Oncogene-Driven Lung Cancer Patient Alliance UK |
|
Roy Castle Lung Cancer Foundation |
|
South Asian Health Foundation |
|
Specialised Healthcare Alliance |
|
Tenovus Cancer Care |
|
UK Lung Cancer Coalition |
Professional groups |
Association of Cancer Physicians |
|
Association of Respiratory Nurse Specialists |
|
British Geriatrics Society |
|
British Institute of Radiology |
|
British Psychosocial Oncology Society |
|
British Thoracic Oncology Group |
|
British Thoracic Society |
|
Cancer Research UK |
|
Lung Cancer and Mesothelioma Clinical Expert Group |
|
Lung Cancer Nursing UK |
|
National Heart and Lung Institute |
|
Primary Care Respiratory Society UK |
|
Royal College of General Practitioners |
|
Royal College of Nursing |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Radiologists |
|
Royal College of Surgeons of England |
|
Royal Pharmaceutical Society |
|
Royal Society of Medicine |
|
Society and College of Radiographers |
|
UK Clinical Pharmacy Association |
|
UK Oncology Nursing Society |
Assessment group |
Cochrane Lung Cancer Group |
|
Cochrane UK |
|
Genomics England |
|
Institute of Cancer Research |
|
MRC Clinical Trials Unit |
|
National Institute for Health Research |
|
Pro Cancer Research Fund |
Associated public health groups |
Public Health Wales |
|
UK Health Security Agency |
Comparator companies |
Accord Healthcare (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine) |
|
Boehringer Ingelheim (nintedanib) |
|
Bristol-Myers Squibb (nivolumab) |
|
Celgene (paclitaxel, nab-paclitaxel) |
|
Consilient Health Ltd (carboplatin, vinorelbine) |
|
Dr Reddy’s Laboratories (docetaxel, pemetrexed) |
|
Fresenius Kabi (docetaxel, paclitaxel) |
|
Fresenius Kabi Oncology (carboplatin, gemcitabine) |
|
Hospira UK (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) |
|
Medac GmbH (vinorelbine) |
|
Merck Sharp & Dohme (pembrolizumab) |
|
Pfizer (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) |
|
Pierre Fabre Ltd (vinorelbine) |
|
Roche Products (atezolizumab, bevacizumab, erlotinib) |
|
Sandoz Ltd (cisplatin) |
|
Sanofi (docetaxel) |
|
Seacross Pharmaceuticals (docetaxel, paclitaxel) |
|
Sun Pharma (carboplatin, gemcitabine) |
|
Teva UK (carboplatin, cisplatin, docetaxel, paclitaxel) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
Allied Health Professionals Federation |
|
Board of Community Health Councils in Wales |
|
British National Formulary |
|
Care Quality Commission |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
National Association for Primary Care |
|
National Pharmacy Association |
|
NHS Alliance |
|
NHS Confederation |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |